Related content

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated)

By Short Mary A.   Schlichting Douglas   Qualy Rebecca L.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2525-2540

Informa Healthcare

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions

By Williams Mark   Macias William   Rustige Joerg  

Intensive Care Medicine, Vol. 33, Iss. 8, 2007-08 ,pp. : 1487-1488

Springer Publishing Company

Access to resources Recommend Favorite

A Multicenter Evaluation of the Safety of Drotrecogin Alfa (Activated) in Patients with Baseline Bleeding Precautions

By  

Current Drug Safety, Vol. 7, Iss. 1, 2012-02 ,pp. : 3-7

Bentham Science Publishers

Access to resources Recommend Favorite

Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs

By Ernst F. R.   Johnston J. A.   Pulgar S.   He J.   Ball D. E.   Young J. K.   Cooper L. M.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-01 ,pp. : 235-244

Informa Healthcare

Access to resources Recommend Favorite

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy

By Dhainaut Jean-François    

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite